Search clinical trials for: Naloxone 2 MG

Total 25443 results

S.L.A. Pharma AG

Completed

Naloxone SR Capsules in Patients With Opioid Induced Constipation

Chronic Pain | Opioid Induced Constipation

Germany, United Kingdom
Rigshospitalet, Denmark

Completed

Effect of High Dose Naloxone on Secondary Hyperalgesia

Pain | Naloxone | Hyperalgesia | Opioid Antagonist

Denmark
Emergent BioSolutions

Completed

Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

Opioid Overdose

United States
New York State Psychiatric Institute

Withdrawn

Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

Suicidal Ideation | Opioid-use Disorder

United States
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use (OPI-14-001)

Drug Overdose

Norway
Leiden University Medical Center
U.S. Food and Drug Administration (FDA)

Recruiting

Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists (ROAR)

Chronic Opioid Use | Opioid Induced Respiratory Depression

Netherlands
University of California, San Francisco

Not yet recruiting

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest (NOPACA)

Heart Arrest, Out-Of-Hospital | Naloxone | Opioid Overdose

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Smerud Medical Research International AS; A/S Den norske...

Completed

Bioavailability of Nasal Naloxone and Injected Naloxone Compared (OPI-15-002)

Drug Overdose

Norway
Samjin Pharmaceutical Co., Ltd.

Completed

A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke

Stroke, Acute

Korea, Republic of
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid (OPI-15-001)

Drug Overdose

Norway
University of Washington
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

Treatment of Menopausal Hot Flashes

United States
Teva Pharmaceuticals USA

Withdrawn

An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects.

Evaluation of QTc Interval
CicloMed LLC
Cmed Clinical Services

Completed

Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Seema Capoor

Completed

Topical Naloxone to Diagnose Ocular Pain

Dry Eye Syndromes | Neuropathic Pain

United States
Judith Feinberg

Unknown

Nasal Naloxone for Narcotic Overdose

Drug Overdose

United States
Alkermes, Inc.

Completed

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence
Galderma R&D

Completed

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

France
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Spain, United States, Italy, Taiwan, Thailand, Poland, Russian Federation, Israel, Ukraine, Mexico, Philippines, Georgia, United Kingdom, Chile, France, Bulgaria, Czechia, Greece, Hungary, Romania, Turkey, Germany, Puerto Rico, Japan
Food and Drug Administration (FDA)
Spaulding Clinical Research LLC

Completed

Clinical Study to Investigate the Pharmacokinetics of Multiple Repeated Doses of Intranasal Naloxone

Healthy Subjects | Pharmacokinetics | Opioid Antagonist

United States
Universitaire Ziekenhuizen KU Leuven

Completed

The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health

Endogenous and Esophageal Sensitivity
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

Advanced Solid Tumor

United States
mads u werner
University of Kentucky

Completed

Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury (TCI-NX-BI)

Healthy Subjects

Denmark
Purdue Pharma LP

Withdrawn

Clinical Outcomes From Nalmefene (COINED)

Opioid Overdose
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Mundipharma Korea Ltd

Completed

An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders (TALENT)

Spinal Disorders
mads u werner
University of Kentucky

Completed

Effect of High-dose Naloxone Following Third Molar Extraction (TME)

Pain, Acute | Healthy Subjects | Hyperalgesia | Sensitization, Central | Inflammations, Endodontic

Denmark
Pocket Naloxone Corp

Completed

Pharmacokinetic Evaluation of a New Naloxone Nasal Swab, Naloxone Nasal Spray, and Intramuscular Naloxone Injection in Healthy Volunteers

Opioid Overdose

Canada
Proteimax Biotechnology Israel LTD

Active, not recruiting

Effect of Consumption of Pep19 on Quality of Life

Quality of Life | Obesity | Sleep Quality

United States
INSYS Therapeutics Inc

Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

Healthy Volunteer

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Tunitas Therapeutics, Inc.
Tunitas Therapeutics Australia Pty Ltd

Terminated

Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects

Allergy and Immunology

Australia
Stanford University
National Institute on Drug Abuse (NIDA)

Completed

5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence

Opioid Withdrawal | Physical Dependence

United States
Aaron R. Mangold

Completed

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Cutaneous Lichen Planus

United States
INSYS Therapeutics Inc

Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

Healthy Volunteer

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Recruiting

Assessing a Clinically-meaningful Opioid Withdrawal Phenotype

Opioid Use Disorder | Opioid Withdrawal | Opioid Craving

United States
Eisai Inc.

Completed

Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects

Purpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic Purpura

Netherlands
Medical College of Wisconsin

Completed

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML

United States
Novartis Pharmaceuticals

Completed

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

Breast Cancer | Hematologic Neoplasms

Netherlands, Switzerland, United Kingdom, United States
Vantia Ltd

Completed

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC)

Nocturia

United States
Eisai Inc.
Eisai Limited

Completed

An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy

Diabetic Neuropathy

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)

Hepatitis C Virus
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder
Zydus Therapeutics Inc.

Active, not recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
R-Pharm

Terminated

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer (IXTEND)

Breast Neoplasms

United States
Norwegian University of Science and Technology
St. Olavs Hospital; University of Iceland

Completed

A Pilot Study of the Bioavailability of Nasal Naloxone

Drug Overdose

Norway
University of Washington

Unknown

Subjective Analgesic Effects of Naloxone and Virtual Reality (Narcan)

Pain

United States
Centre for Addiction and Mental Health
Academic Health Science Centres

Completed

Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation

Constipation

Canada
Duke University
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075 (Pharm-OUD-Care)

Opioid Use Disorder

United States

Search clinical trials for: Naloxone 2 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations